Which class of drugs does baricitinib/baricitinib belong to?

Baricitinib is an oral small molecule targeted drug that belongs to the "JAK inhibitor" (Janus kinase inhibitor) category. Its mechanism of action is mainly by selectively inhibiting the activity of JAK1 and JAK2 enzymes, thereby interfering with multiple cytokine signaling pathways and weakening the over-activation state of the immune system. This mechanism makes baricitinib show broad prospects in the treatment of a variety of diseases with inflammation and immune disorders as the core pathological mechanisms.

In terms of clinical indications, baricitinib was initially approved for patients with moderately to severely active rheumatoid arthritis, especially those who have failed to respond to traditional antirheumatic drugs orTNF-α inhibitors. In addition, it has also been used in other disease areas where the JAK pathway is active, such as rheumatoid arthritis, alopecia areata, etc., and has been included in some national guidelines as one of the immune regulation options in the treatment of severe inflammatory reactions related to COVID-19. Its broad-spectrum anti-inflammatory effect is due to its ability to intervene in a variety of inflammatory cytokines, such as interleukin-6 (IL-6), interferon-γ, etc. These pathways are usually closely related to the progression of the disease.

It is worth noting that, unlike early immunosuppressive drugs, baricitinib has the advantages of precise targeting and rapid onset of action. At the same time, as an oral agent, it improves patients' long-term medication compliance. However, due to its regulatory effect on the immune system, it may also bring potential side effects such as increased risk of infection, thrombophilia, abnormal liver enzymes, etc. Therefore, the risk-benefit ratio needs to be assessed and monitored under the guidance of a professional physician. JAK inhibitors are also being increasingly used in the treatment of inflammatory diseases, and baricitinib, as an important representative in this field, shows broad application prospects.

Reference materials:https://go.drugbank.com/drugs/DB11817